Vertex Pharmaceuticals Maps Growth Beyond CF at Cantor Conference

Vertex Pharmaceuticals outlined an expanded commercial and clinical strategy at the Cantor Global Healthcare Conference, centered on its recent acquisition of Crinetics and planned renal-product launch efforts. The transaction broadens Vertex’s growth opportunities, but integration execution risk remains a key consideration for investors.